One of the key takeaways from the meeting, and from phase I of CHL UK, was that we tested and learned together for a whole year, but it’s now time to put our energy into what works.
With food allergies on the rise, and 15 million Americans allergic to one or more foods, chances are good that someone you work with, go to school with or are friends with will have a food allergy. According to the Centers for Disease Control and Prevention, food allergies are a growing food safety and public health concern that affects between 4 and 6 percent of young people in the U. S. Allergic reactions can be life threatening and have far-reaching effects on the individual and their families, as well as the school, college or university they attend.
The Novartis Foundation and its partners will highlight progress towards transforming the health of the poorest populations at the 9th European Congress on Tropical Medicine and International Health (ECTMIH) held in Basel from September 6 – 10. Updates on nine Novartis Foundation-sponsored healthcare delivery models and disease elimination programs in low- and middle-income countries will be showcased in scientific sessions and sponsored-symposia.
Novartis has renewed its pledge with the World Health Organization (WHO) to work to end leprosy by extending its donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO in handling the donation and logistics. Overall it is expected that the program will reach an estimated 1.3 million patients during the next five years. This is part of the company’s commitment in 2012 to the London Declaration on Neglected Tropical Diseases.
The business landscape is reorienting itself and you can almost hear priorities shifting toward change-readiness and the bigger picture. And in this...
